AstraZeneca's $2.1B Sino Biopharm licensing deal targets a dual formulation version of the inhaled COPD drug class that Merck's Ohtuvayre currently owns as a single format product.
AstraZeneca is paying Sino Biopharm $2.1 billion for global ex-China rights to a COPD drug that comes in two formulations. TQC3721, the asset at the center of the deal, is in Phase 3 in China as a nebulized treatment and in Phase 2 as a dry-powder inhaler. Merck's rival in the same drug class, Ohtuvayre (ensifentrine), is approved only as a nebulized treatment, which limits prescribing to pulmonology clinics and patients comfortable with a nebulizer. The format gap is what AZ is buying.
TQC3721 is an inhaled dual PDE3/PDE4 inhibitor, a class that relaxes airway smooth muscle via PDE3 and cuts lung inflammation via PDE4. That combination is the only mechanism with an approved COPD entrant, and AstraZeneca is now positioning itself as the first credible second mover. The broader COPD maintenance market is dominated by LABA/LAMA inhalers and, more recently, biologics like dupilumab, none of which target the same combined bronchodilation-and-inflammation mechanism. Sino Biopharm, via its Chia Tai Tianqing subsidiary, called TQC3721 a potential best-in-class candidate, though that framing is the seller's positioning rather than an independent read on the mid-stage data.
The Phase 2 readout, as reported by FierceBiotech, showed peak FEV1 improvement of up to 147 mL at Week 4. That figure is a Sino-reported lung-function measure; cross-trial comparison to Verona/Ohtuvayre FEV1 deltas is not directly available in the published excerpt, and any "better than Ohtuvayre" framing reflects the seller's positioning rather than an adjudicated head-to-head.
The commercial benchmark for the bet is now public. Ohtuvayre generated $131M in Q1 2026, its first full quarter of revenue. Annualized, that is roughly a $525M run-rate, and Merck CEO Robert Davis has publicly framed the asset as carrying "multibillion-dollar peak commercial potential." Merck paid about $10B to acquire Verona for Ohtuvayre. AZ is now paying a $200M upfront plus up to $1.9B in milestones, per the TipRanks deal recap, a fraction of the Verona price but with a meaningfully later data package and into a class that has just been commercially validated.
Sino Biopharm's strategy is the second thread. The Hong Kong-listed company announced a separate respiratory licensing expansion with GSK in the same week, running a portfolio out-licensing model across multiple global pharma buyers at once. That parallel flow suggests the AZ transaction is the largest single Sino ex-China respiratory outlicense to date rather than a one-off relationship, and gives Sino leverage in subsequent negotiations with either party.
What AZ gets, in the simplest framing, is the ability to compete for the COPD maintenance patient who cannot or will not use a nebulizer. A DPI, if the Phase 2 data holds, can be written as a take-home prescription, expanding the prescriber base beyond the pulmonology clinics that drive Ohtuvayre volume today. AZ has not publicly stated this as the strategic rationale, and the framing in trade press that AZ is "crashing the PDE3/4 party" is reporter synthesis rather than a verbatim company statement. The structural thesis here is the mechanism, not the messaging.
The watch items are concrete. The Chinese Phase 3 nebulized program is the first Phase 3 readout for TQC3721, on a timeline not yet publicly disclosed. The DPI Phase 2 has to clear its own enrollment and dose-finding milestones. Merck's full-year 2026 Ohtuvayre number, due in early 2027, will set the ceiling on what a credible second-mover can claim as a peak-sales target when AZ eventually guides.